New data is beginning to shed light on covid-19-related IP filings, but major patent landscape uncertainties pose dangers for research organisations and access to medicine.
Life sciences companies and research institutions responded to the pandemic with a wave of innovation, seeking to develop vaccines, drugs and diagnostics to tackle covid-19. While beneficial from an immediate public health point of view, this swell of activity means that organisations operating in the eld may need to navigate a crowded landscape of new patent rights.
Though interesting early data about covid-19 patent rights led in recent months is now available, life science organisations must be wary of the substantial uncertainty continues to shroud the IP landscape. She argued that this could hinder further innovation and access to coronavirus-related inventions...
